MRK
Merck & Co. Inc.
Price History
Why Is MRK ▲ Up Today?
+0.46%
Full AI analysis generates after market close. Showing live price data.
Financial Highlights
Income Statement
Balance Sheet
Cash Flow
Highly Regarded Analysis
Executive Summary
Merck & Co., Inc. (MRK) is a multinational pharmaceutical company, known as Merck in the U.S. and Canada and MSD elsewhere. It holds a strong position in the pharmaceutical industry with a diversified portfolio, including key products like the immuno-oncology drug Keytruda and the HPV vaccine Gardasil. The company boasts a robust pipeline and solid financial health, evidenced by recent positive Phase 3 trial results for its individualized mRNA-based neoantigen therapy (intismeran) combined with Keytruda for melanoma. However, the looming patent expiration of Keytruda in 2028 presents a significant challenge to future revenue streams. Merck's Q2 2026 worldwide sales were $16.6 billion, reflecting continued strength in oncology and animal health.
Bull Case
Merck's strong and diversified product portfolio, led by Keytruda in immuno-oncology and Gardasil in vaccines, provides a solid foundation. The company possesses a robust pipeline with significant potential new growth drivers, notably the recent positive Phase 3 results for the individualized mRNA-based neoantigen therapy (intismeran) developed with Moderna, which could significantly boost its oncology franchise post-Keytruda patent expiration. Management anticipates over $70 billion in commercial opportunities from more than 20 pipeline products. Strong financials and ongoing investments in R&D further support future growth and the ability to navigate competitive landscapes.
Bear Case
The primary risk for Merck is the impending loss of patent exclusivity for its top-selling drug, Keytruda, in 2028, which currently accounts for nearly half of its pharmaceutical revenue. This creates concerns about the company's ability to maintain growth without this major revenue driver and the potential for increased competition from generics and biosimilars. The stock's current premium valuation, as reflected by its high P/E ratio, suggests that upside potential may be limited. There are execution risks associated with bringing new pipeline products to market successfully, and a high dividend payout ratio could become unsustainable if earnings do not recover as expected.
Technical Outlook
MRK is currently trading at $152.23, near its 52-week high of $156.92. The stock has demonstrated strong momentum, with a 76.70% increase over the last year and a 16.55% rise over the past month. The 52-week low for the stock is $77.58.
Fundamental Health
Merck maintains a strong financial position with a market capitalization of $372.91 billion. While its trailing P/E ratio is high at 121.21, the forward P/E is noted at 55.7x, still considered rich for a large-cap pharma. The company offers a dividend yield of 2.22%. In 2025, Merck reported revenues of $65.0 billion and R&D expenses of $15.8 billion, with a net income of $18.26 billion. Although Merck reported a net loss of $0.13 per share in Q2 2026 due to acquisition charges, full-year 2026 revenue guidance is set between $66.3 billion and $67.3 billion. Analysts forecast an earnings growth of 31.9% per year. The debt-to-equity ratio is moderate at 128.6%.
Key Catalysts
- Full dataset for intismeran autogene at the ESMO conference (October 23-27, 2026)
- Further clinical trial readouts, including Sac-TMT data at ESMO and TL1A trial results
- New product launches and expanded indications for therapies such as WINREVAIR (pulmonary arterial hypertension) and ENFLONSIA (RSV prevention)
- Strategic acquisitions and partnerships to bolster the pipeline and diversify revenue streams
Sources
This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.
Go Deeper on MRK
Key Stats
Next Earnings
MRK News
No recent news for MRK.
